Peritoneal Access for Intracavitary Chemotherapy
- 1 January 1986
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Drug Delivery
- Vol. 3 (2) , 157-161
- https://doi.org/10.1089/cdd.1986.3.157
Abstract
Direct intraperitoneal instillation of many chemotherapeutic agents can markedly increase total peritoneal drug exposure and may be useful for the treatment of ovarian carcinoma and mesothelioma. The use of a totally implanted access system (Port-a-Cath™) reduces the risk of inadvertent bowel damage, and infection associated with repeated intraperitoneal instillation of drugs. In addition, patient acceptance is better in comparison to catheters that protrude through the skin. Catheter failure due to the formation of adhesions around the outside of the catheter remains a major problem.Keywords
This publication has 4 references indexed in Scilit:
- Totally implantable system for peritoneal access.Journal of Clinical Oncology, 1984
- Reduction of postoperative pelvic adhesions with intraperitoneal 32% dextran 70: a prospective, randomized clinical trialFertility and Sterility, 1983
- Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.Journal of Clinical Investigation, 1981
- The effect of volume on the distribution of substances instilled into the peritoneal cavityGynecologic Oncology, 1978